Document is current
Any future updates will be listed below
-
Authors
Bottomly, Daniel https://orcid.org/0000-0001-7191-0990
Zheng, Christina
Creason, Allison L. https://orcid.org/0000-0001-5724-1276
Mitri, Zahi I. https://orcid.org/0000-0001-8765-7723
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
McWeeney, Shannon K.
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 16 May 2025
First Online: 13 June 2025
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: G.B.M. has licensed technologies to Myriad Genetics and NanoString; is on the SAB or is a consultant to Amphista, Astex, AstraZeneca, BlueDot, Ellipses Pharmaceuticals, ImmunoMET, Leapfrog Bio, Bruker/Nanostring, Neophore, Nerviano, Nuvectis, Pangea, PDX Pharmaceuticals, Qureator, RyboDyne, Signalchem Lifesciences, Turbine and Zentalis Pharmaceuticals; and has stock/options/financial interests in Bluedot, ImmunoMet, Nuvectis, RyboDyne, SignalChem Lifesciences, and Turbine; Sponsored research: AstraZeneca, Zentalis and Nanostring.
